Utilizes a proprietary hybrid, expert-curated AI platform, leveraging key partners’ proprietary data, chem/bio tools, knowledge, and expertise to identify highly valuable molecular mechanisms of pathology, rationally design therapies, accelerate discovery, and optimize the development of best-in-class and first-in-class treatments.

Mobilizes a range of high-value chem/bio models and platforms engineered for rational small-molecule design and discovery, including broad classes of oral protein degraders and molecular glues, protein–protein interaction inhibitors, covalent and reversible binders, and synthetic lethality dual inhibitors, to deliver superior medical advantages of our drug candidates.

Deploys multi-target and multi-property optimization, predictive pharmacology, and biomarker strategies to accelerate nonclinical and early clinical development.

Organizes a global industrial and academic R&D partnering network, leveraging access to functional biology, diversified formulation and manufacturing capabilities, and highly defined patient cohorts.